Renoprotective Effect of the Mineralocorticoid Receptor Antagonist Esaxerenone
Open Access
- 12 May 2021
- journal article
- Published by Japanese Circulation Society in Circulation Reports
- Vol. 3 (6), CR-21-0024-337
- https://doi.org/10.1253/circrep.cr-21-0024
Abstract
Background:The effects of mineralocorticoid receptor antagonists, including the newly introduced esaxerenone, on renal function remain uncertain. Methods and Results:This retrospective study was performed on patients who received esaxerenone for resistant hypertension between November 2019 and June 2020. Trends in the estimated glomerular filtration rate (eGFR) were compared between the 6-month period before esaxerenone treatment (pre-treatment period) and the 6-month treatment period on esaxerenone. Twenty-six patients (15 men), with a median age of 70 years (interquartile range [IQR] 51–73 years) and a median systolic blood pressure of 146 mmHg (IQR 139–156 mmHg), were included in the study and completed 6 months of esaxerenone therapy without any adverse events. eGFR decreased significantly during the pre-treatment period (from 66.6 to 59.5 mL/min/1.73 m2; P=0.003), whereas eGFR was unchanged during the treatment period (from 59.5 to 61.8 mL/min/1.73 m2; P=0.15). The median change in eGFR differed significantly between the treatment and pre-treatment periods (3.8 [IQR −4.2, 6.8] vs. −6.1 [IQR −11.1, 1.8] mL/min/1.73 m2, respectively; P=0.008). Conclusions:Esaxerenone may have renoprotective effects when administered to treat hypertension. Further studies are needed to understand which patient populations may see greater renoprotective benefits with esaxerenone.Keywords
This publication has 15 references indexed in Scilit:
- Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with MicroalbuminuriaClinical Journal of the American Society of Nephrology, 2019
- Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trialsThe Lancet Diabetes & Endocrinology, 2019
- 2018 ESC/ESH Guidelines for the management of arterial hypertensionEuropean Heart Journal, 2018
- Correction to: Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice GuidelinesHypertension, 2018
- 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice GuidelinesHypertension, 2018
- Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonistEuropean Journal of Pharmacology, 2015
- Incidence, Predictors, and Outcomes Related to Hypo- and Hyperkalemia in Patients With Severe Heart Failure Treated With a Mineralocorticoid Receptor AntagonistCirculation: Heart Failure, 2014
- Incidence, Determinants, and Prognostic Significance of Hyperkalemia and Worsening Renal Function in Patients With Heart Failure Receiving the Mineralocorticoid Receptor Antagonist Eplerenone or Placebo in Addition to Optimal Medical TherapyCirculation: Heart Failure, 2014
- Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and preventionThe Lancet, 2013
- Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertensionJournal of Hypertension, 2013